<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03527784</url>
  </required_header>
  <id_info>
    <org_study_id>85/2018</org_study_id>
    <nct_id>NCT03527784</nct_id>
  </id_info>
  <brief_title>Prestoma-Trial for Parastomal Hernia Prevention</brief_title>
  <official_title>PRESTOMA- A Prospective Randomized Controlled Multicenter Trial Comparing Three Meshes for Prevention of Parastomal Hernia After Abdominoperineal Resection for Rectal Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oulu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oulu</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prestoma Trial is designed to compare the safety and efficiency of three different meshes and
      techniques to prevent parastomal hernia after laparoscopic or robotic-assisted
      abdominoperineal resection for rectal adenocarcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Parastomal hernia after permanent colostomy formation is a common problem. The European
      Hernia Society recommends the use of prophylactic mesh when the stoma is constructed. So far,
      there're no trials comparing the methods to prevent the parastomal hernia.

      Prestoma Trial is designed to compare the most researched retromuscular mesh (Parietene Macro
      by Medtronic) with two different types of intraperitoneal meshes (Parietex Parastomal by
      Medtronic and Dynamesh IPST) in parastomal hernia prevention after laparoscopic or
      robotic-assisted abdominoperineal resection for rectal adenocarcinoma.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 3, 2018</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prestoma is a prospective randomized controlled multicenter trial.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Subject is blinded of the mesh used. Outcome at 12 month follow-up is assessed by surgeon who was not involved in the operation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of parastomal hernia</measure>
    <time_frame>1 year</time_frame>
    <description>The primary outcome is incidence of parastomal hernia at 12 months follow up, detected clinically or on CT scan.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surgical infections</measure>
    <time_frame>30 days</time_frame>
    <description>Surgical infections due to primary surgery, defined by CDC (Centers for Disease Control) definition for surgical site infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>30 days</time_frame>
    <description>The incidence of complications defined by Clavien-Dindo Classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stoma related complications</measure>
    <time_frame>5 years</time_frame>
    <description>Any complications related to stoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reoperation rate</measure>
    <time_frame>5 years</time_frame>
    <description>Reoperation needed for any reason related to previous surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operative time</measure>
    <time_frame>30 days</time_frame>
    <description>Total time needed in operation theatre and time needed for mesh application</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>30 days</time_frame>
    <description>Length of stay at the hospital.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>5 years</time_frame>
    <description>Quality of life measured by The RAND 36-Item Health Survey 1.0 which assess eight health concepts: physical functioning, role limitations caused by physical health problems, role limitations caused by emotional problems, social functioning, emotional well-being, energy/fatigue, pain, and general health perceptions with a scale 0-100, higher the score, better the quality of life.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Rectal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Parietene Macro</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Parietene Macro is a macroporous synthetic mesh.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parietex Parastomal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Parietex Parastomal is a synthetic mesh with resorbable collagen lining to prevent attachments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dynamesh IPST</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dynamesh IPST is synthetic mesh with central tube to accommodate bowel tightly designed to prevent and treat parastomal hernia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Parietene Macro</intervention_name>
    <description>Parietene Macro is used on retromuscular sublay position. The bowel is brought through opening in the middle of the mesh.</description>
    <arm_group_label>Parietene Macro</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Parietex Parastomal</intervention_name>
    <description>Parietex Parastomal is used on intraperitoneal onlay position by modified Sugarbaker technique to prevent parastomal hernia.</description>
    <arm_group_label>Parietex Parastomal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dynamesh IPST</intervention_name>
    <description>Dynamesh IPST is used on intraperitoneal onlay position to prevent parastomal hernia</description>
    <arm_group_label>Dynamesh IPST</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Abdominoperineal resection for rectal cancer with permanent end colostomy, either by
             laparoscopic technique or robotic assistance

          -  18 years or older

          -  Patient has a life expectancy of at least 12 months.

          -  Patient signs the Informed consent and agrees to attend all study visits.

        Exclusion Criteria:

          -  Abdominoperineal resection by laparotomy or conversion to laparotomy

          -  Patient with a comorbid illness or condition that would preclude the use of surgery
             (ASA 4-5).

          -  Patients with concurrent or previous malignant tumors within 5 years before study
             enrollment

          -  Patients with T4b tumors which impose a multi-organ resection

          -  Rectal malignancy other than adenocarcinoma

          -  Potentially curable resection not possible

          -  Patient undergoing emergency procedures

          -  Planned rectal surgery along with major concomitant procedures (e.g. hepatectomies,
             other intestinal resections).

          -  Metastatic disease with life expectancy of less than 1 year

          -  Pregnant or suspected pregnancy

          -  Patients living geographically distant and/or unwilling to return for follow-ups or
             comply with all study requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisa Mäkäräinen-Uhlbäck, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oulu University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elisa Mäkäräinen-Uhlbäck, M.D.</last_name>
    <phone>+35883152282</phone>
    <email>elisa.makarainen-uhlback@ppshp.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tero Rautio, Ph.D.</last_name>
    <phone>+35883152817</phone>
    <email>tero.rautio@ppshp.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Monika Carpelan-Holmström, Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jyväskylä Central Hospital</name>
      <address>
        <city>Jyväskylä</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matti Kairaluoma, Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Anu Ehrlich, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne Fagerström, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisa Mäkäräinen-Uhlbäck, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seinäjoki Central Hospital</name>
      <address>
        <city>Seinäjoki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tarja Pinta, Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kirsi Lehto, Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jukka Karvonen, Ph.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2018</study_first_submitted>
  <study_first_submitted_qc>May 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2018</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rectal adenocarcinoma</keyword>
  <keyword>abdominoperineal resection</keyword>
  <keyword>hernia prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Hernia</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

